, /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that it will host a sponsored symposium to present the largest and most diverse set of data to date from a cohort of 50 patients treated with the CAR in KYV-101, an autologous, fully human anti-CD19 CAR T-cell immunotherapy. The data support the differentiated safety profile of the CAR in various indications, including a 30-patient data set that spans >28 day follow-up in various autoimmune disease patients with early efficacy data.
A 12-month follow-up of the first patient treated with KYV-101 for myasthenia gravis will also be presented. The symposium titled "Anti-CD19 CAR T-Cell Therapy in Rheumatologic Autoimmune Diseases and Beyond" will take place on , from . The symposium will offer insights on the ongoing clinical trials and named-patient initiatives from leading experts in rheumatology and neurology, including: A will be hosted later in the day featuring Georg Schett, M.
D., vice president of research at the Friedrich-Alexander-University in Erlangen, , and , M.D.
, M.P.H.
Both are members of Kyverna's Scientific Advisory Board. Additionally, Kyverna will showcase two posters on focusing on the preclinical development of KYV-201 - the Company's allogeneic product candidate - and proteomic markers associated with CAR T therapeutic response in autoimmune d.